Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA.
Reduction of an enzyme activity required for the lysosomal degradation of glycosaminoglycan (gag) chains will result in a mucopolysaccharidosis (MPS) disorder. Substrate deprivation therapy (SDT), a potential therapy option for MPS with residual enzyme activity, aims to reduce the synthesis of gag chains, the natural substrate for the deficient enzyme. Reduced substrate levels would balance the reduced level of enzyme in patient cells, resulting in normalized gag turnover. Rhodamine B, a nonspecific inhibitor, reduced gag synthesis in a range of normal and MPS cells and also decreased lysosomal storage of gag in MPS VI (72%) and MPS IIIA (60%) cells. Body weight gain of male MPS IIIA mice treated with 1 mg/kg rhodamine B was reduced compared with untreated MPS IIIA mice and was indistinguishable from that of normal mice. Liver size, total gag content, and lysosomal gag was reduced in treated MPS IIIA animals as was urinary gag excretion. Lysosomal gag content in the brain was also reduced by treatment. The alteration in MPS IIIA clinical pathology by rhodamine B, combined with the observation that treatment had no effect on the health of normal animals, demonstrates the potential for SDT in general as a therapy for MPS disorders.
Roberts
Ainslie L K
AL
Department of Genetic Medicine, Children, Youth, and Women's Health Service, North. Adelaide, SA 5006 Australia.
Thomas
Belinda J
BJ
Wilkinson
Ashley S
AS
Fletcher
Janice M
JM
Byers
Sharon
S
D000818:Animals; D001921:Brain / Q000166:cytology / Q000187:drug effects; D002478:Cells, Cultured; D004195:Disease Models, Animal; D006025:Glycosaminoglycans / Q000037:antagonists & inhibitors* / Q000096:biosynthesis* / Q000652:urine; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008297:Male; D051379:Mice; D009084:Mucopolysaccharidosis III / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D009929:Organ Size / Q000187:drug effects; D012235:Rhodamines / Q000627:therapeutic use*; D015430:Weight Gain / Q000187:drug effects
D006025:Glycosaminoglycans; D012235:Rhodamines; C029773:rhodamine B